(CHAT) Thanks for the gold link, Carl. Of course there are market forces working here -:)
Since you asked where I am looking for gains -- in biotechnology. DEPO, in particular, since it is 2 months from FDA resolution on its 1st product, and has shown up on the STO.
In general, some contraction for the multi-national big pharmas that provide much of the cash for biotechs, will make the biotech barrel a little smaller, and the fish correspondingly larger. I am focusing on biotechs with adequate capital, unique development platforms, late stage products, and low cash burn. Premier among these is ArQule (ARQL). Some others worth consideration in this sale include BCHE, GLIA, and SEPR. |
